Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
Fjoralba Zeka, … , Pieter Mestdagh, Jo Vandesompele
Fjoralba Zeka, … , Pieter Mestdagh, Jo Vandesompele
Published December 6, 2018
Citation Information: JCI Insight. 2018;3(23):e97021. https://doi.org/10.1172/jci.insight.97021.
View: Text | PDF
Research Article Genetics Oncology

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

  • Text
  • PDF
Abstract

In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of noninvasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in 2 independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis, and overall survival revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential abundance analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in both patient cohorts. Increasing levels of these miRNAs were also observed in serum from xenografted mice bearing human neuroblastoma tumors. Moreover, murine serum miRNA levels were strongly associated with tumor volume. These findings were validated in longitudinal serum samples from metastatic neuroblastoma patients, where the 9 miRNAs were associated with disease burden and treatment response.

Authors

Fjoralba Zeka, Anneleen Decock, Alan Van Goethem, Katrien Vanderheyden, Fleur Demuynck, Tim Lammens, Hetty H. Helsmoortel, Joëlle Vermeulen, Rosa Noguera, Ana P. Berbegall, Valérie Combaret, Gudrun Schleiermacher, Geneviève Laureys, Alexander Schramm, Johannes H. Schulte, Sven Rahmann, Julie Bienertová-Vašků, Pavel Mazánek, Marta Jeison, Shifra Ash, Michael D. Hogarty, Mirthala Moreno-Smith, Eveline Barbieri, Jason Shohet, Frank Berthold, Tom Van Maerken, Frank Speleman, Matthias Fischer, Katleen De Preter, Pieter Mestdagh, Jo Vandesompele

×

Figure 7

Proportional increase of metastatic disease miRNA markers in serum from mice engrafted with human neuroblastoma cells.

Options: View larger image (or click on image) Download as PowerPoint
Proportional increase of metastatic disease miRNA markers in serum from ...
(A) Average miRNA abundance (log10 normalized values) in murine serum from 8 engrafted mice 6 days before engraftment and 11 days and 25 days after engraftment. i, miR-873-3p is a human specific miRNA assay; asterisks represent significant increase of miRNA abundance over time based on linear mixed-effects model analysis (P < 0.05, 1-way ANOVA).(B) Luciferase fluorescence assessment of tumor volume 14 days and 23 days after engraftment for 5 of 8 mice in A.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts